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We describe a young girl with dilated cardiomyopathy, long QT syndrome, and possible energy deficiency. Two
major sequence changes were identified by whole exome sequencing (WES) and mitochondrial DNA analysis
that were interpreted as potentially causative. Changes were identified in the KCNH2 gene and mitochondrial
tRNA for cysteine. A variation was also seen inMYPBC3. Since the launch ofWES as a clinically available technol-
ogy in 2010, there has been concern regarding the identification of variants unrelated to the patient's phenotype.
However, in cases where targeted sequencing fails to explain the clinical presentation, the underlying etiology
could be more complex than anticipated. In this situation, the extensive reach of this tool helped explain both
her phenotype and family history.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Whole exome sequencing (WES) is a powerful tool that canbeutilized
for the identification of pathogenicmutations. However it can also identi-
fy variants unrelated to phenotype. Here, we present a patient identified
to have multiple mutations by WES that more effectively describe their
complex phenotype than a single change.
Our patient initially came to attention for dilated cardiomyopathy
(DCM) but also had a history of sensorineural hearing loss. Her clinical
course was complicated as she had required extracorporeal membrane
oxygenation (ECMO) on several occasions without a clear precipitating
event. Her cardiac and family history prompted concern that there may
be more than one cause for her findings. However extensive previous
testing had been non-diagnostic, so WES was performed during a par-
ticularly serious and protracted hospital admission. Initial WES inter-
pretation implicated genes associated with DCM, long QT syndrome
(LQTS) in addition to multiple variants. Mitochondrial DNA sequencing
identified a transfer RNA variant.
Typically, DCM can present with heart failure, cardiac arrhythmias or
sudden cardiac death in an otherwise seemingly healthy individual. It
has an estimated prevalence of 36 per 100,000 individuals and 25–30%
of those cases are familial [1–3]. Inheritance patterns may be autosomal
dominant, autosomal recessive, X-linked ormitochondrial.Massive paral-
lel sequencing technologies have allowed the identification of the respon-
sible gene in up to 40% of cases of familial DCM, making possible the
screening of asymptomatic at-risk individuals [4–6].
LQTS is another leading cause of sudden cardiac death in children
and its prevalence has been estimated to be as high as 1 in 2000 [7].
Gene sequencing panels currently available can identify mutations in
75% of patients with congenital LQTS [4].
Although the prevalence of congenital LQTS in families with DCM
has not been studied, both conditions are most commonly inherited in
an autosomal dominant manner. The contribution of a change in mito-
chondrial transfer RNA and LQTS in the context of a DCM variant of un-
known significance could have potentiated a fatal scenario.
2. Case presentation
A 4 year old girl with sensorineural hearing loss and speech delay
initially presented to the emergency room due to breathing difficulty.
Physical exam revealed a non-dysmorphic appearance with evidence
of cardiovascular compromise and generalized hypotonia. Dilated eye
exam was normal. Family history was significant for an older sister
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with speech delay and hearing loss who passed suddenly at age
2 years. The autopsy interpretedher death secondary tomyocarditis, pre-
sumed to be of viral etiology. Both parents and two younger sisters were
reportedly healthy although none had been evaluated formally for
hearing or cardiac concerns. Two older paternal half-sisters were also re-
portedly healthy.
Upon admission, an echocardiogramrevealeddilated cardiomyopathy
(DCM). Endomyocardial biopsy showed no signs of myocarditis, negative
viral DNA/RNA (adenovirus, CMV, EBV, enterovirus, parvovirus) andmild
to moderate subendothelial fibrosis. Skeletal muscle biopsy was normal
and included histochemical stains for mitochondrial oxidative phosphor-
ylation defects (cytochrome C oxidase and succinate dehydrogenase),
and analysis for ragged red fibers. Biochemical analyses to include plasma
amino acids, urine organic acids, an acylcarnitine profile, and total and
free carnitine were also normal.
During this initial presentation and hospitalization, the patient
required extracorporeal membrane oxygenation (ECMO) with a left ven-
tricular assist device (LVAD) andwas evaluated for heart transplantation,
but her cardiac function recovered prior to the anticipated surgery
(Fig. 1). During the next four years, she was hospitalized five more
times with acute heart failure and decompensation. Additional molecular
genetic testing completedduring these hospitalizations included chromo-
somal oligoarray (GeneDx, 2011), dilated cardiomyopathy sequencing
panel (GeneDx, 2011, 27 genes), connexin 26 and connexin 30, Otoscope
Fig. 1. 1–3: Initial presentation in congestive heart failure. (2) and (3) were obtained prior to placement on ECMO after rapidly worsening cardiac function. (1) Mildly dilated left atrium
and ventricle. (2) parasternal short axis image showing minimal motion of the interventricular septum and excursion of the posterior wall, suggesting severely decreased left ventricular
function. The calculated shortening fraction (SF) was 10% (normal range 28–40%). (3) Apical 4 chamber view showing generalized dilatation with thin left ventricular walls, consistent
with dilated cardiomyopathy (DCM). The left ventricle also showsmild hypertrabeculation of theposteriorwallwhich can represent non-compaction of the left ventricle. There is a throm-
bus in the right atrium (shown with the arrow). Images 4 and 5 were obtained between hospitalizations and show complete echocardiographic resolution of her failed systolic function.
(4) Parasternal short axis view showing a thicker ventricular septum and posterior walls more consistent with non-compaction/hypertrophic cardiomyopathy (HCM) when compared
with (2). Note the normal excursion of both walls. SF was 37%. (5) Apical 4 chamber view showing normal systolic function and significant hypertrabeculation.
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Table 1
Results of WES clinical testing (Baylor, Molecular Diagnostics Laboratory) in the initial proband.
Gene Protein Function Position Isoform Location Variant
(amino acid)
Variant
(protein)
Genbank accession
numbers
Parent
of
origin
Pathogenicity Predicted
phenotype
Polyphen/SiFT Polymorphism
or ESP5400
status
Mutations per initial clinical reports
MYBPC3 Myosin binding
protein C
Binds myosin to modulate
contraction
Chr11:47367777 NM_000256 Exon 11 c. 1071CNT p.Arg358X ENSG00000134571 Mother Likely
pathogenic
HCM/DCM NA/NA Not reported
KCNH2 Membrane
potassium
channel
Potassium flow during
repolarization
Chr7:150647150 NM_172058 Exon 9 c.2503del C p.Leu835fs ENSG0000055118 Father Likely
pathogenic
LQTS2 NA/NA Not reported
MT-TC tRNA Cys Mitochondrial cysteine
transport
m.5814TNC HGNC:7477 Mother Pathogenic Mitochondrial
myopathy
MELAS
asymptomatic
Variants
MYPN Myopalladin Interacts with nebullete in
cardiac muscle and nebulin
in skeletal muscle in Z-lines
Chr10:69934085 NM_032578 Exon 11 c.2236ANG p.Thr746Ala Mother VUS DCM/HCM rs147287437
TTN Titin Major component in
striated muscle
Chr2:179455631 NM_133378 Exon
253
c.53117CNT p.Pro177706Leu ENSG00000155657 Father VUS CM, MD,
myopathy
ESP5400
TTN Titin Major component in
striated muscle
Chr2:179449188 NM_133378 Exon
260
c.57388CNT p.Arg19130Cys ENSG00000155657 Father VUS CM, MD,
myopathy
ESP5400
TTN Titin Major component in
striated muscle
Chr2:179603991 NM_003319 Exon 45 c.12880ANC p.Asn4294HIs ENSG00000155657 Father VUS CM, MD,
myopathy
ESP5400
TTN Titin Major component in
striated muscle
Chr2:179585257 NM_133378 Exon 77 c.19500CNG p.Asn6500Lys ENSG00000155657 Father VUS CM, MD,
myopathy
ESP5400
TTN Titin Major component in
striated muscle
Chr2:
179612873
NM_133379 Exon 46 c.14254ANC p.Ser4752Arg ENSG00000155657 Mother VUS CM, MD,
myopathy
rs146504870
COG6 Component of
the oligomeric
Golgi complex 6
Component of the conserve
oligomeric Golgi complex
Chr13:40235007 NM_020751 Exon 3 c.358ANG p.Ser120Gly ENSG00000133103 VUS CDG III rs139313781
GIPC3 GIPC PDZ
domain
containing
family
Role in hair bundle survival Chr19:3590081 NM_133261 Exon 6 c.832GNA p.Glu278Lys ENSG00000179855 Novel VUS Deafness AR15 Novel
MED23 Mediator
complex subunit
23
Role in identification of
enhancer sites in DNA for
transcription
Chr6:131908846 NM_004830 Exon 29 c.4080GNT p.Val1360Val ENSG00000112282 VUS Intellectual
disability (AR
18)
rs138742804
LAMA2 Laminin Component of basement
membrane
Chr6:129759787 NM_000426 Intronic c.5969-4GNA ENSG00000196569 Novel VUS MD (Merosin) Novel
UPF3B UPF3 regulator
of nonsense
transcripts
homolog B
Regulates post-splicing
multiprotein complex
ChrX:118971901 NM_080632 Exon 10 c.1121GNA p.Arg374His ENSG00000125351 Father VUS Intellectual
disability
(X-linked 14)
rs143538947
49
M
.J.G
uillen
Sacoto
etal./M
olecular
G
enetics
and
M
etabolism
Reports
3
(2015)
47–54
panel (University of Iowa 2012, 66 genes), were all non-diagnostic. The
contents of each of these studies are listed in Appendix A.
Her average length of hospital stay was 41 days and after prolonged
periods of cardiac and nutritional support she would fully recover to
cardiac baseline. One prolonged hospitalization with apparent end
organ failure required over threemonths of ECMO therapy. The chronic-
ity and severity of these episodes were unusual particularly with the
family history of sudden death and sensorineural hearing loss, and
more aggressive molecular analysis was pursued.
3. Molecular diagnostics
Whole exome sequencing (WES) inclusive ofmitochondrial DNA test-
ing targeting 162 nuclear and 37 mitochondrial genes (Baylor College of
Medicine/MitomeNGSSM) was requested and revealed a maternally
inherited “pathogenic”mutation in MYBPC3 and a likely pathogenic mu-
tation in KCNH2 that was paternally inherited. Pathogenicity was deter-
mined by Mercury 1.0 (Baylor) [8]. All reported mutations and variants
are listed in Table 1 and Appendix A. The MYBPC3 mutation was later
reclassified as a variant of unknown significance (VUS).
Our patient also had an apparently homoplasmic mutation affecting
themitochondrial transfer RNA Cysteine (tRNA Cys) that was interpreted
as pathogenic (Table 1 and Appendix A).
Neither one of the parents nor other older relatives had a known
history of cardiac disease (Pedigree in Appendix B). The family was
informed of the testing results and extensive genetic counseling was pro-
vided. The patient eventually died at 8 years of age after decompensation
following a sudden illness. One of the patient's younger sisterswas subse-
quently diagnosed with sensorineural hearing loss and developmental
delay. Serial echocardiogram and EKG analyses have been normal, and
she has never been hospitalized. Recent molecular testing showed that
she has the same change in mitochondrial tRNA Cys in addition to the
MYBPC3 variant. Testing of her deceased older sister was not able to be
completed.
4. Discussion
The combination of hearing loss and cardiomyopathy, in our patient
and her deceased sister, suggested an underlying genetic etiology.
However the initially available tools for genetic testing failed to provide
a diagnosis until massive parallel sequencing of the entire exome became
available.
Common causes of dilated cardiomyopathy in children includemyo-
carditis, infiltrative disease and drugs. Approximately 50% of cases are
considered idiopathic of which 20–50% are thought to be familial, de-
pending on the screening methods used [3,9]. Our patient was found
Fig. 2. The 3 pathogenic mutations and their interaction in the heart are depicted. Loss of function mutations in KCNH2 and a membrane potassium channel are associated with long QT
syndrome type 2 (LQTS2). In LQTS2 loudnoises can trigger torsades de pointes, ultimately leading to syncope, seizures or sudden cardiac death. Cardiacmyosin-binding protein C, encoded
byMYBPC3, bindsmyosin andwhenphosphorylatedmediates contraction. Themytochondrial transfer RNA-cysteine (tRNACys) localizeswithin themitochondria and abnormal synthesis
of mitochondrial proteins and/or oxidative stress imbalances have been associatedwith DCM [20]. We postulate that abnormalities in cardiac myosin-binding protein C were responsible
for the dilated cardiomyopathy present in our patient and the mitochondrial dysfunction secondary to the mutation in the tRNACys had an additive effect on the severity of the phenotype.
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to have a likely pathogenic mutation in the MYBPC3 gene, usually asso-
ciated with hypertrophic cardiomyopathy (40%), but also reported in 4%
of patients with familial or idiopathic dilated cardiomyopathy [10]. It
was not reported abnormal in the initial cardiomyopathy panel ordered
for this patient although included.
Interestingly, WES also revealed a mutation in KCNH2 associated
with LQTS type 2 [11]. Although, we have no evidence of long QT in
our patient, individuals with mutations in KCNH2 are at increased risk
of sudden cardiac death, even in the absence of electrocardiographic ab-
normalities [12,13].
Mitochondrial genome sequencingwas ordered concurrently to con-
sider an explanation to the patient's hearing loss, initial presentation of
hypotonia, and severe recurrent episodes of heart failure. Mitochondrial
disease can be secondary to alterations inmitochondrial proteins, which
in turn can be encoded by nuclear or mtDNA [14]. Many mitochondrial
mutations also affect the tRNA genes. Pathogenic mutations have been
reported in 1 in 200 live births, however the prevalence of mitochondrial
disorders is about 1 in 10,000 [15]. In general,mitochondrial disease refers
to disorders of the respiratory chain, which tend to effect in organs with
high energy demand, like the myocardium, and mitochondrial cardiomy-
opathy is awell-recognized entity [16,17]. Not surprisingly,mitochondrial
dysfunction has been associated with cardiomyopathy [18,19] and muta-
tions in the mitochondrial genome affecting tRNA have been identified in
individuals with DCM [20,21].
Mitochondrial DNA is solely maternally inherited in most instances
[22], and in this family, as two of four children have been identified
with homoplasmic mutations, the laboratory interpretation (personal
discussion with Baylor Miraca Genetics Laboratories) is that there is a
probability of maternal homoplasmy as well. The mutation in the tRNA
Cys, found in our patients has been reported in other patients with en-
cephalomyopathy andmitochondrialmyopathy, Mitochondrial Enceph-
alopathy, Lactic Acidosis and Stroke-like episodes (MELAS), hearing loss
as well as asymptomatic family members [23–25]. As SNHLwas present
in both our patient and her sister who did not have the long QT muta-
tion, we feel that the mitochondrial tRNA Cys change is the underlying
etiology.
Additionally, we feel that the mitochondrial mutation may have
contributed to or even potentiated the clinical presentation of car-
diomyopathy and the seemingly complete remission after prolonged
and intensive cardiac support (Fig. 1). There are reports of a child
with both long QT and hypertrophic cardiomyopathy mutations as
well as a child with same tRNA Cys mutation who hypertrophic
cardiomyopathy and mitochondrial myopathy [26,27], but none of
a patient or family similar to ours.
WES also allows the determination of the parent of origin in the case
of inherited mutations. All family members carrying either mutation
have been recommended to undergo routine clinical screening along
with genetic testing. Screening offered to family members included
echocardiography and EKGs.
The exact cause of the sudden cardiac death in the older sister is un-
clear. It is quite possible that she also carried the samemutations or var-
iants in mitochondrial tRNA Cys, MYBPC3, KCNH2, or a combination of
more than one. Post-mortem genetic testing could have potential bene-
fit for the family [26], thoughwas not possible in this case. Nevertheless,
information regarding both the mechanisms and related risks to all sur-
viving family members may prove to be invaluable for their health.
5. Conclusions
Aswe continue to accumulate information on variants found bywhole
exome sequencing, it is likely thatwewill be able to better classify themas
benign or pathogenic. While mutations in any one of these three genes
can convey pathogenicity in a variablemanner, it is clear that in combina-
tion, initial cardiac stress also became a risk for both rhythm disturbances
and dilated cardiomyopathy, ultimately leading to functional compro-
mise. The identification of the two individual gene mutations via clinical
testingmay have provided an initial clue, but not the full physiologic phe-
notype for this child's cardiac risks and intermingled pathology (Fig. 2).
Multiple episodes of full cardiac support via ECMO allowed themyocardi-
um to rest but the underlying genetic risks to metabolic stress may have
ultimately led to this child's passing. We also feel that it is important to
consider the possible contribution of the sequence variation in MYBPC3,
as may also have potentiated pathogenicity under the unique circum-
stance of mitochondrial compromise and arrhythmia.
This case demonstrates that multiple underlying genetic mecha-
nisms should be considered in extraordinary clinical presentations.
We offer that multiple genetic mutations and/or variants of unclear
significance may be acting synergistically to compound phenotype.
Thoughtful identification can have a profound effect upon both the
patient's care and counseling to other family members regarding their
own health risks.
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Gene test Gene Dx Microarray 2011 GeneDX dilated cardiomyopathy
panel 2011
Otoscope Saint Francis Whole exome Mitochondrial
DNA
Results No deletions duplication No mutations identified No mutations
identified
No mutations
identified
Mutations and variations within Mutations
Genes 180,000 oligonucleotide probes LMNA ATCG1 Cx26/GJB2 Per publshed protocol Reid et al. MT-TC (m.5814TNC)
LDB3/ZASP CCDC50 CX30/GJB6
TTNT2 CDH23 Mutations
DES CLDN14 KCNH2 (c.2503delC)
SGCD CLRN1 Variations
ACTC1 COCH MYBPC3 (c.1071CNT)
PLN COL11A2 MYPN (c.2236ANG)
MYH7 CRYM TTN (c.53117CNT)
TPM1 DRNA5 TTN (c. 57388CNT)
TNNI3 DIAPH1 TTN (c. 12880ANC)
TAZ DSPP TTN (c.19500CNG)
(continued on next page)
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(continued)
Gene test Gene Dx Microarray 2011 GeneDX dilated cardiomyopathy
panel 2011
Otoscope Saint Francis Whole exome Mitochondrial
DNA
Results No deletions duplication No mutations identified No mutations
identified
No mutations
identified
Mutations and variations within Mutations
TTR ESPN TTN (c. 14254ANC)
MYBPC3 ESSRB COG6 (c. 358ANG)
LAMP2 EYA4 GIPC3 (c. 832GNA)
MTTK GIPC3 MED23 (c.4080GNT)
MTTL1 CX26/GJB2 LAMA2 (c. 5969-4GNA)
MTTL2 GJB3 UPF3B (c. 1121GNA)
MTTQ CX30/GJB6
MTTH GPR96
MTTD GPSM2
MTTI GRHL2
MTTV GRXCR1
MTTS1 HGF
MTTS2 ILDR1
MTND1 KCNQ4
MTND5 LHFPL5
MTND6 LOXHD1
LRTOMT
MARVELD2
miR-96
miR-182
miR-183
MTRNR1
MTTS1
MYH14
MYH9
MYO1A
MYO15A
MYO3A
MYO6
MYO7A
OTOA
OTOF
PCDH15
PJVK
POU3F4
POU4F3
PRPS1
PTPRQ
RDX
SLC17A3
SLC26A4
SLC26A5
STRC
TECTA
TJP2
TMC1
TMIE
TMPRSS3
TPRN
TRIOBP
USH1C
USH1G
USH2A
WFS1
WHRN
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